MX344018B - Forma farmacéutica para combatir la sumisión química de un medicamento. - Google Patents

Forma farmacéutica para combatir la sumisión química de un medicamento.

Info

Publication number
MX344018B
MX344018B MX2012015104A MX2012015104A MX344018B MX 344018 B MX344018 B MX 344018B MX 2012015104 A MX2012015104 A MX 2012015104A MX 2012015104 A MX2012015104 A MX 2012015104A MX 344018 B MX344018 B MX 344018B
Authority
MX
Mexico
Prior art keywords
pharmaceutical form
medicament
chemical submission
combating chemical
combating
Prior art date
Application number
MX2012015104A
Other languages
English (en)
Other versions
MX2012015104A (es
Inventor
Herry Catherine
Contamin Pauline
Dupau Emmanuel
Original Assignee
Ethypharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm Sa filed Critical Ethypharm Sa
Publication of MX2012015104A publication Critical patent/MX2012015104A/es
Publication of MX344018B publication Critical patent/MX344018B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/84—Systems specially adapted for particular applications
    • G01N21/88—Investigating the presence of flaws or contamination
    • G01N21/94—Investigating contamination, e.g. dust
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/02—Food
    • G01N33/14—Beverages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con una forma farmacéutica para combatir la sumisión química, que comprende un ingrediente activo y por lo menos un compuesto que permite la modificación inmediata de las características organolépticas de una bebida en la cual se introduce la forma farmacéutica, dicho compuesto se selecciona del grupo que comprende un opacificador, un agente fluorescente, partículas flotantes, partículas que son perceptibles en la boca, microgránulos efervescentes, y las mezclas de los mismos; también se relaciona con el uso de estos compuestos para combatir la sumisión química y con un método para combatir la sumisión química al usar dichas formas farmacéuticas.
MX2012015104A 2010-07-06 2011-07-05 Forma farmacéutica para combatir la sumisión química de un medicamento. MX344018B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1055491A FR2962331B1 (fr) 2010-07-06 2010-07-06 Forme pharmaceutique pour lutter contre la soumission chimique, methode la mettant en oeuvre
PCT/FR2011/051601 WO2012007672A1 (fr) 2010-07-06 2011-07-05 Forme pharmaceutique pour lutter contre la soumission chimique d'un medicament

Publications (2)

Publication Number Publication Date
MX2012015104A MX2012015104A (es) 2013-05-28
MX344018B true MX344018B (es) 2016-12-02

Family

ID=43661911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012015104A MX344018B (es) 2010-07-06 2011-07-05 Forma farmacéutica para combatir la sumisión química de un medicamento.

Country Status (13)

Country Link
US (2) US20130108556A1 (es)
EP (1) EP2590632B1 (es)
JP (1) JP2013533874A (es)
KR (1) KR20130043180A (es)
CN (1) CN103118667B (es)
AU (1) AU2011278140B2 (es)
CA (1) CA2802404C (es)
ES (1) ES2733732T3 (es)
FR (1) FR2962331B1 (es)
IL (1) IL223887B (es)
MX (1) MX344018B (es)
WO (1) WO2012007672A1 (es)
ZA (1) ZA201300077B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2962550B1 (fr) * 2010-07-06 2013-06-14 Ethypharm Sa Methode pour lutter contre la soumission chimique, utilisation d'agent colorant pour lutter contre la soumission chimique et composition pharmaceutique permettant la mise en oeuvre de la methode

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
FR2787715B1 (fr) * 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
FR2790387B1 (fr) 1999-03-01 2001-05-18 Prographarm Laboratoires Comprime orodispersible presentant une faible friabilite et son procede de preparation
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
AU2001232020A1 (en) * 2000-02-09 2001-08-20 West Pharmaceutical Services Drug Delivery And Clinical Research Centre Limited Floating drug delivery composition
ITMI20011446A1 (it) * 2001-07-06 2003-01-06 Altergon Sa Composizioni farmaceutiche di principi attivi suscettibili di somministrazione illecita
FR2829932B1 (fr) * 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
FR2829933B3 (fr) * 2001-09-21 2004-03-12 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US8906413B2 (en) * 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
GB2410087B (en) 2003-12-19 2008-11-19 Bloomsbury Innovations Ltd Drug assay kit for testing beverages
AU2005295482B2 (en) * 2004-10-15 2011-03-31 Supernus Pharmaceuticals Inc. Less abusable pharmaceutical preparations
EP1681048A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Orally disintegrating composition of olanzapine or donepezil
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
WO2008033351A2 (en) * 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations
EP2572705B1 (en) * 2007-10-01 2017-09-13 Laboratorios Lesvi, S.L. Orodispersible tablets
WO2009104080A2 (en) * 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use

Also Published As

Publication number Publication date
MX2012015104A (es) 2013-05-28
JP2013533874A (ja) 2013-08-29
US20130108556A1 (en) 2013-05-02
HK1184050A1 (en) 2014-01-17
EP2590632A1 (fr) 2013-05-15
IL223887B (en) 2018-08-30
ES2733732T3 (es) 2019-12-02
CN103118667A (zh) 2013-05-22
AU2011278140A1 (en) 2013-01-17
US20170016925A1 (en) 2017-01-19
ZA201300077B (en) 2014-03-26
CA2802404A1 (fr) 2012-01-19
FR2962331B1 (fr) 2020-04-24
EP2590632B1 (fr) 2019-04-17
KR20130043180A (ko) 2013-04-29
WO2012007672A1 (fr) 2012-01-19
AU2011278140B2 (en) 2015-07-09
CA2802404C (fr) 2019-08-13
CN103118667B (zh) 2015-09-16
FR2962331A1 (fr) 2012-01-13

Similar Documents

Publication Publication Date Title
WO2010017545A3 (en) Triazole compounds that modulate hsp90 activity
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
MY160456A (en) Benzodiazepine bromodomain inhibitor
UA95975C2 (ru) N-метиламинометилизоиндольные соединения, композиции, содержащие их, и способы их применения
WO2012027065A3 (en) Combination therapy for treatment of disease
MX340822B (es) Formulaciones para suministro oral de adsorbentes en el intestino.
EP2021797A4 (en) N-2,2,4-bis (1,1-dimethylethyl) -5-hydroxy-phenyl-1,4-dihydro-4-oxoquinol-3-carboxamide
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2011128630A3 (en) Anti-abuse gelled pharmaceutical compositions
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2008128740A8 (en) Titration of tapentadol
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
ZA201004214B (en) Dipeptidyl peptidase-iv inhibiting compounds,methods of preparing the same,and pharmaceutical compositions containing the same as active agent
WO2011028044A3 (ko) 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2011028043A3 (ko) 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
IL213409A0 (en) Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
WO2008112368A3 (en) Phenylalkylcarboxylic acid delivery agents
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
WO2011009039A3 (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
WO2014078576A3 (en) Oral transmucosal drug delivery system

Legal Events

Date Code Title Description
FG Grant or registration